Acorda Therapeutics (ACOR) Surges After Kyle Bass Loses Patent Challenge – ValueWalk Premium
Acorda

Acorda Therapeutics (ACOR) Surges After Kyle Bass Loses Patent Challenge

The U.S. Patent and Trademark Office on Monday rejected an attempt by hedge fund manager Kyle Bass to challenge two patents relating to Acorda Therapeutics Inc.’s flagship multiple sclerosis drug Ampyra.

Mirroring the development, shares of Acorda surged 31% to $38 in after-hours trading on Monday, and are currently up 15% in market trading on Tuesday.

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

0